semaglutide tirzepatide retatrutide vs vs Retatrutide: What the Research Actually Shows Retatrutide Helped Adults With Diabetes

I., Crian, G., & Buzoianu, A

The most common are gastrointestinal: nausea (experienced by 20-40% of patients, usually diminishing over time), vomiting, diarrhea, constipation, abdominal discomfort, and reduced appetite (which contributes to therapeutic effects but can be excessive for some patients)

For patients exploring weight management, GLP-1 peptide therapies (such as compounded semaglutide or tirzepatide from PlexusDx) have substantially more robust clinical evidence supporting appetite regulation and metabolic improvement

The good news is that emerging technologies such as chemosensitivity testing and genetic profiling are helping to better match patients with treatments that are more likely to effectively treat their specific cancer (Grigsby 2013